Would you like to react to this message? Create an account in a few clicks or log in to continue.

約友討論區 交友網頁ptt 免費 交友app 台灣交友平台軟體 dcard 正經交友app 2021 110 聊天技巧 怎麼 跟女生聊天 交友 APP 交友 軟體 推薦 交友 網站 評比 探探 愛情公寓 PTT 買可樂 約跑 跑步 約炮 約砲 約泡 網交 相親 拍拖 脫單 Pairs 派愛族 Zuvio 校園 Cheers 緣圈 ( 威而鋼哪裡買 https://www.poxet.tw/goods-195.html

必利勁 | 壯陽持久藥 | 情趣小物 | 持久噴劑 | 老二增大 | 增強性慾 | 卡瑪格 | 雙效果凍威而鋼 | 印度犀利士 | 威格拉 | 犀利士20mg | 威而鋼口溶錠 | 犀利士5mg | 威而柔女用威而鋼 | 超級犀利士 | 壯陽藥散賣試用 | 必利勁 | 必利吉 | 泰國果凍威而鋼 | 樂威壯 | 威而鋼100mg |

不夠硬怎麼辦 威而鋼哪裡買

您沒有登錄。 請登錄註冊

The Fc fusion therapeutics market is anticipated to grow at an annualized rate of over 10%, claims Roots Analysis

發表新主題  回復主題

向下  內容 [第1頁(共1頁)]



Since the approval of Enbrel:registered: in 1998 for the treatment of rheumatoid arthritis, Fc fusion therapies have evolved into a prominent class of therapeutics; currently, several therapies are being developed for a variety of disease indications
Roots Analysis has announced the addition of Fc Fusion Therapeutics Market, 2021-2030” report to its list of offerings.
With 13 drugs approved in the European Union and the US, Fc fusion therapeutics are considered to be one of the most successful classes of IgG-based products. The success of these biopharmaceutical products can be attributed to their diverse biological and pharmacological properties, including an extended serum half-life, enhanced Fc mediated effector functions, easy expression, increased stability and aggregation resistance, modulated immunogenicity and improved safety profiles, for the treatment of a wide range of disease indications
To order this 130+ page report, which features 95+ figures and 140+ tables, please visit 
Key Market Insights 
Presently, more than 115 Fc fusion therapeutics are approved / under development
Over 60% of the aforementioned candidates are being evaluated in clinical stages; of these, 50 molecules are in advanced phases (Phase II and above) of clinical trials. This is followed by more than 30% of the [url=https://www.rootsanalysis.com/uploads/documents/Fc Fusion Therapeutics Market, 2021-2030 (Order Form).pdf]Fc fusion therapeutics[/url] which are already marketed for various disease indications. It is worth noting that majority of the pipeline therapies (18) are being developed to target PD-L1 for the treatment of oncological disorders.
More than 25 companies claim to be engaged in the development of Fc fusion therapeutics
Post 2001, there has been a significant rise in the number of companies working in this domain. It is worth noting that majority (48%) of the firms engaged in this domain are based in North America, followed by those headquartered in Asia-Pacific (38%) and Europe (3%).
Over 1,450 clinical trials have been registered for the evaluation of Fc fusion therapeutics, globally 
Of these, most of the trials were / are being conducted in North America (48%). Within this region, more than 50% of the total patients were enrolled in trials focused on the evaluation of these therapeutics. This was followed by studies being conducted in Europe and Asia Pacific.
Close to 200 grants have been awarded to support research on Fc fusion therapeutics, since 2010
Around USD 68 million have been awarded to various organizations working in this domain, since 2010. Further, almost 80% of the total grants were awarded for a support period of 1-5 years.
Over 10,000 patents have been filed / granted related to Fc fusion therapeutics, since 2018
Of these, majority (45%) of the patents were filed / granted in North America, followed by Asia-Pacific (21%). Moreover, in addition to the industry players, various patents related to Fc fusion therapeutics were filed by academic institutes as well.
Partnership activity within this domain has grown significantly between 2015 and 2021
The maximum number of partnerships for Fc fusion therapeutics were signed in 2020. Further, product development and commercialization (32%) emerged as the most popular type of partnership model adopted by stakeholders in this domain. This was followed by product development agreements (26%), acquisitions (21%), and manufacturing and supply agreements (11%).
Funding and Investments within this domain has shown a significant growth between 2016 and 2021
Around USD 450 million was raised in the Fc fusion therapeutics domain, through various funding rounds. It is worth mentioning that majority of the amount (~USD 550 million) was raised through venture capital financing.
At present, therapies targeting ophthalmological disorders represent majority of the market share (in terms of sales revenue)
We believe that, in the foreseen future the trend is likely to remain the same. The market opportunity within this therapeutic area is likely to be distributed among indications, such as ophthalmological disorders, and hematological diseases. This is followed by genetic disorders which represent over 30% of the market share.
To request a sample copy / brochure of this report, please visit this 
Key Questions Answered
§  Who are the leading players involved in the development of Fc fusion therapeutics?
§  Which geographies are the most active in conducting clinical trials on Fc fusion therapeutics?
§  Which are the leading funding organizations providing grants for Fc fusion therapeutics?
§  Which partnership models are commonly adopted by industry stakeholders engaged in the Fc fusion therapeutics market?
§  How is the current and future market opportunity likely to be distributed across key market segments?
The financial opportunity within the Fc fusion therapeutics market has been analyzed across the following segments:
§  Type of Target Indication
§  Neutropenia
§  Graft Versus Host Disease
§  Breast Cancer
§  Rheumatoid Arthritis
§  Non- Small Cell Lung Cancer
§  Neovascular (wet) Age-related Macular Degeneration (AMD)
§  Hemophilia A
§  Neuromyelitis Optica Spectrum Disorders
§  Systemic Lupus Erythematosus
§  Type of Fusion Molecule
  • Antibody
  • Cytokine
  • Growth Factor
  • Receptor ECD
  • Others

§  Type of Therapy
§  Combination
§  Monotherapy
§  Route of Administration (RoA)
§  Subcutaneous
§  Intravenous
§  Intravitreal
§  Geographical Regions 
§  North America
§  Europe
§  Asia- Pacific
§  Latin America
§  Middle East
§  Rest of the World
The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), a description of the services offered, details on recent developments and an informed future outlook.
§  Alphamab Oncology
§  Amgen
§  Acceleron Pharmaceuticals
§  Bristol-Myers Squibb
§  Sanofi
For additional details, please visit 
or email [email=sales@rootsanalysis.com?subject=Large%20Volume%20Wearable%20Injectors%20Market%20(4th%20Edition)-%20Press%20Release%20Query]sales@rootsanalysis.com[/email]
You may also be interested in the following titles: 
1.       Regulatory T-Cell Therapies (Tregs) Market , 2021–2035
2.       CD47 Targeting Therapeutics Market , 2021-2035
3.       Light Activated Therapies Market , 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you'd like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091

回頂端  內容 [第1頁(共1頁)]

發表新主題  回復主題

可以 在這個版面回復文章

必利吉 | 不夠硬怎麼辦 | 陽痿早洩怎麼辦 | 夜尿症 | 延時噴霧劑 持久液 | 液態威而鋼 | 威而鋼學名藥 | 早洩怎麼辦 | SWAG討論區 | 印度壯陽藥 | 雙效犀利士 | 泰國果凍威 | 威而鋼口溶錠 | 男性功能障礙 | 必利吉 | 犀利士5mg治療攝護腺肥大陽痿 | 必利勁 | 樂威壯 | 交友討論區 |